Get the Stockscreener App
1.645
3.46%
0.055
Senti Biosciences Inc stock is traded at $1.645, with a volume of 65,931.
It is up +3.46% in the last 24 hours and down -17.34% over the past month.
Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.
See More
Previous Close:
$1.59
Open:
$1.57
24h Volume:
65,931
Relative Volume:
0.24
Market Cap:
$43.03M
Revenue:
$1.79M
Net Income/Loss:
$-70.90M
P/E Ratio:
-0.1059
EPS:
-15.54
Net Cash Flow:
$-34.95M
1W Performance:
+8.22%
1M Performance:
-17.34%
6M Performance:
-58.46%
1Y Performance:
-38.64%
1-Day Range:
$1.57
$1.66
1-Week Range:
$1.46
$1.66
52-Week Range:
$1.46
$16.94
Senti Biosciences Inc Stock (SNTI) Company Profile
Name
Senti Biosciences Inc
Sector
Industry
Phone
(650) 239-2030
Address
2 CORPORATE DRIVE, FIRST FLOOR, SOUTH SAN FRANCISCO
Compare SNTI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SNTI
Senti Biosciences Inc
|
1.645 | 41.86M | 1.79M | -70.90M | -34.95M | -15.54 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Senti Biosciences Inc Stock (SNTI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-06-25 | Initiated | Laidlaw | Buy |
| Oct-07-22 | Initiated | Morgan Stanley | Equal-Weight |
Senti Biosciences Inc Stock (SNTI) Latest News
Key resistance and support levels for Senti Biosciences Inc.Portfolio Risk Summary & Real-Time Sentiment Analysis - Newser
What technical models suggest about Senti Biosciences Inc.’s comeback2025 Year in Review & Daily Stock Trend Reports - Newser
Top chart patterns to watch in Senti Biosciences Inc.2025 Key Highlights & Smart Swing Trading Alerts - Newser
Will Senti Biosciences Inc. benefit from macro trendsTrade Analysis Summary & Safe Swing Trade Setups - Newser
Using economic indicators to assess Senti Biosciences Inc. potentialPortfolio Return Report & Stock Portfolio Risk Management - Newser
How to integrate Senti Biosciences Inc. into portfolio analysis toolsMarket Growth Review & High Conviction Investment Ideas - Newser
Does Senti Biosciences Inc. have declining or rising EPSWeekly Loss Report & Community Shared Stock Ideas - thegnnews.com
Will Senti Biosciences Inc. announce a stock split2025 Geopolitical Influence & Stepwise Entry and Exit Trade Signals - newsyoung.net
Senti Biosciences to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech - 富途牛牛
Senti Biosciences to present at Webull Financial Corporate Connect webinar. - AInvest
Senti Bio CEO to Showcase Gene Circuit Platform at Webull's Biotech Investment Series - Stock Titan
Senti Biosciences Posts Increased Losses Amid Strategic Moves and Raising $35.2M in Private Placement - AInvest
Senti Biosciences Inc. Pullback Analyzed — Is It Time to ExitJuly 2025 WrapUp & Verified High Yield Trade Plans - beatles.ru
Laidlaw Initiates Coverage on Senti Bio with Buy Rating and $5 Target Price - AInvest
Is This a Bottoming Phase for Senti Biosciences Inc.2025 Valuation Update & Risk Managed Investment Signals - beatles.ru
Senti Biosciences Reports Increased Losses Amid Strategic Moves - TipRanks
Senti Biosciences shares rise 3.38% after-hours after announcing Phase 2 dose selection for SENTI-202. - AInvest
Senti Biosciences shares fall 1.32% intraday after announcing participation in a Virtual Investor 'What This Means' segment. - AInvest
Senti Bio Participates in Virtual Investor 'What This Means” Segment Discussing The Phase 2 Dose and Schedule Selection for SENTI-202 in its Clinical Trial for Acute Myeloid Leukemia - The Manila Times
Breakthrough AML Treatment Advances: Senti Bio Reveals Phase 2 Dosing Strategy for Novel CAR-NK Cell Therapy - Stock Titan
Momentum divergence signals in Senti Biosciences Inc. chartTrading Opportunities Forecast by AI Insight - Newser
What makes Senti Biosciences Inc. stock price move sharplyReal Market Tracker with Price Action Tools - Newser
Senti Biosciences Inc. stock chart pattern explainedLow Exposure Strategy with Sector Analysis - Newser
Senti Biosciences Inc. Stock Fails to Break Resistance Traders ReactIntraday Trend Analysis for Fast Gains Released - beatles.ru
Using data tools to time your Senti Biosciences Inc. exitBreakout Monitoring with Momentum Analysis - Newser
Chardan Capital Reaffirms “Buy” Rating for Senti Biosciences (NASDAQ:SNTI) - Defense World
Senti Biosciences Inc Reports Q2 2025 Earnings: EPS at -$0.56, Revenue Misses Estimates at $0 Million - AInvest
Senti Biosciences: Chardan Capital Raises Buy Rating, PT to $12 - AInvest
Senti Biosciences: A High-Risk Bet on Biotech's Future? - AInvest
Senti Biosciences completes dose finding in AML therapy trial By Investing.com - Investing.com Australia
Senti Biosciences completes dose finding in AML therapy trial - Investing.com
Senti Bio reports Q2 results, SENTI-202 clinical development advances. - AInvest
Senti Bio Reports Second Quarter 2025 Financial Results and Confirms Next Data Milestone for Phase 1 SENTI-202 Study in Acute Myeloid Leukemia (AML) Expected Q4 2025 - The Manila Times
Senti Bio Advances AML Treatment: Phase 2 Dose Confirmed, FDA Orphan Drug Status Secured - Stock Titan
How Senti Biosciences Inc. stock performs during market volatilityTen-Year Sector Performance and Summary Analysis - Newser
Sandstorm Gold Royalties Backs Royal Gold’s Kansanshi Acquisition - The Globe and Mail
Senti Biosciences shares rise 3.49% premarket after confirming recommended Phase 2 dose for SENTI-202. - AInvest
Tools to assess Senti Biosciences Inc.’s risk profileAnnual Market Behavior and Sector Summary - Newser
Will Senti Biosciences Inc. stock recover after recent dropIn-Depth Stock Trading Volume Analysis - Newser
Is Senti Biosciences Inc. stock overhyped or has real potentialConsistent Gain Plan with AI Support - Newser
Senti Bio Determines Recommended Phase 2 Dose (RP2D) in Phase 1 Study of SENTI-202 for the Treatment of Relapsed/Refractory Hematologic Malignancies, Including Acute Myeloid Leukemia - The Manila Times
Breakthrough AML Treatment: Senti Bio's Cell Therapy Shows 67% Complete Remission at Phase 2 Dose - Stock Titan
Senti Biosciences Inc. Forms Double Bottom Pattern — Eyes on BreakoutConsistent Gain Investment Strategies Emerge - metal.it
Is Senti Biosciences Inc. stock entering bullish territoryFree Sector Based Breakout Stock Forecast - Newser
What is Senti Biosciences Inc. company’s growth strategyAchieve consistent profits with proven methods - Jammu Links News
How does Senti Biosciences Inc. generate profit in a changing economyCapitalize on market momentum for maximum gains - Jammu Links News
What are the technical indicators suggesting about Senti Biosciences Inc.Capitalize on market momentum for maximum gains - Jammu Links News
Is Senti Biosciences Inc. stock overvalued or undervaluedFree Stock Market Real-Time Monitoring - Jammu Links News
Why Senti Biosciences Inc. stock attracts strong analyst attentionFast Entry Strategy with Price Prediction - Newser
Senti Biosciences Inc Stock (SNTI) Financials Data
Revenue
Net Income
Cash Flow
EPS
Senti Biosciences Inc Stock (SNTI) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Lu Timothy K | CEO |
Feb 06 '25 |
Sale |
4.36 |
545 |
2,376 |
82,082 |
| Rajangam Kanya | Pres. & Chief Med. & Dev. Off. |
Feb 04 '25 |
Sale |
4.07 |
1,297 |
5,279 |
8,803 |
| Rajangam Kanya | Pres. & Chief Med. & Dev. Off. |
Feb 06 '25 |
Sale |
4.37 |
182 |
795 |
8,621 |
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):